Search

Displaying results 2821 - 2830 of 10000 in total
  1. Drug

    Moexipril

    go.drugbank.com/drugs/DB00691
    ApprovedInvestigational

    Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension).

    Categories: Antihypertensive Agents Indicated for Hypertension
  2. Drug

    2,2'-Dibenzothiazyl disulfide

    go.drugbank.com/drugs/DB14201
    Approved

    2,2'-Dibenzothiazyl disulfide is an accelerator used in the processing process for natural and synthetic rubber and plastic regeneration. It is also a known allergen and dermatological sensitizer. … Sensitivity to 2,2'-Dibenzothiazyl disulfide may be identified with a clinical patch test.

  3. Drug

    Vindesine

    go.drugbank.com/drugs/DB00309
    ApprovedInvestigationalWithdrawn

    Vinblastine derivative with antineoplastic activity against cancer. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (antineoplastic combined chemotherapy protocols).

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  4. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    In December of 2006 GSK announced a decision to discontinue the development of brecanavir for the treatment of HIV. The decision was based on issues regarding the formulation of the drug. … Brecanavir (VX-385) an orally active aspartic protease inhibitor (PI), under investigation by Vertex and GlaxoSmithKline for the treatment of HIV.

  5. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    [L45424] The EMA approved this drug the following year, in February 2024, and Health Canada in March 2025 for the same condition. … Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties.

  6. Drug

    DPI-221

    go.drugbank.com/drugs/DB06121
    Experimental

    DPI-221 is an investigational drug and a selective agonist for the δ-opioid receptor.

  7. Drug

    Cisapride

    go.drugbank.com/drugs/DB00604
    ApprovedWithdrawn

    The FDA issued a warning letter regarding this risk to health care professionals and patients. … In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.

    Categories: Drugs for Functional Gastrointestinal Disorders
  8. Drug

    Virus Specific T-Cell

    go.drugbank.com/drugs/DB15735
    Investigational

    Virus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources. … These T-cells are then isolated from the donor and expanded in a culture to generate more VSTs.

    Synonyms: HLA-matched Virus Specific T Cells, Partially HLA-matched Virus Specific T Cell
  9. Drug

    Otenabant

    go.drugbank.com/drugs/DB11745
    Investigational

    Otenabant has been investigated for the treatment of Obesity.

  10. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label]. … The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.

    Synonyms: l-Alpha-1-palmitoyl-2-oleoylglycerophosphoglycerol